Company to File Fiscal 2012 Third Quarter 10-Q After the Close of Market Today
St. Louis, MO – February 9, 2012 – K-V Pharmaceutical Company (the “Company”) (NYSE: KVa/KVb) today reported updated performance metrics for Makena®.
“We continue to advance our commercialization strategy for Makena® by actively engaging the medical and payer communities on the differences between FDA-approved Makena® and unapproved compounded 17P formulations,” said Greg Divis, President and CEO of K-V Pharmaceutical and President of Ther-Rx. “Our efforts are driving improved performance metrics and we are intensely focused on continuing to grow our market share.”
Fiscal 2012 Form 10-Q and Investor Conference Call
The Company will be filing its fiscal 2012 third quarter Form 10-Q with the U.S. Securities & Exchange Commission (SEC) after the close of market today. The Company will host an investor conference call on Friday, February 10, 2012 at 8:30 a.m. EDT to discuss the information contained in the Form 10-Q as well as provide a general update on other company matters. Participants can listen to the conference call by dialing 866-843-0890 and providing code 4088697. To access the live web cast of the conference call, please go to the investor relations portion of the Company’s website under “Conference Calls” at
Please log-in or dial-in at least 10 minutes prior to the start time to ensure a connection.
A replay of the call will also be available for seven days by calling 877-344-7529 and providing code 10009958. An archived version of the webcast will be accessible for 30 days at www.kvpharmaceutical.com.
About K-V Pharmaceutical Company
K-V Pharmaceutical Company is a specialty branded pharmaceutical company with a primary focus in the area of women’s healthcare. As such, we are committed to advancing the health of women across all the stages of their lives.
For further information about K-V Pharmaceutical Company, please visit the Company’s corporate Website at www.kvpharmaceutical.com.
Cautionary Note Regarding Forward-looking Statements
This press release contains various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and which may be based on or include assumptions concerning our operations, future results and prospects. Such statements may be identified by the use of words like “plan,” “expect,” “aim,” “believe,” “project,” “anticipate,” “commit,” “intend,” “estimate,” “will,” “should,” “could,” “potential” and other expressions that indicate future events and trends.
All statements that address expectations or projections about the future, including, without limitation, statements about product launches, governmental and regulatory actions and proceedings, market position, revenues, expenditures and the impact of the recall and suspension of shipments on revenues, and other financial results, are forward-looking statements.
All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the PSLRA’s “safe harbor” provisions, we provide the following cautionary statements identifying important economic, competitive, political, regulatory and technological factors, among others, that could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions. Such factors include (but are not limited to) the following: